Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...

Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Q3 2025 Earnings Call October 30, 2025 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

HBcAb-positive, HBsAg-negative people with HIV can safely switch from tenofovir-containing ART without clinically significant HBV reactivation.

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy ...

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...